Monthly Prescribing Reference

Butrans Transdermal System available soon for chronic pain

BUTRANS (buprenorphine) 5mcg/hr, 10mcg/hr, 20mcg/hr transdermal patch by Purdue Purdue announced that Butrans (buprenorphine) Transdermal System will be available for ordering the week of January 10, ...
Monthly Prescribing Reference

Butrans Transdermal System approved for chronic pain

BUTRANS (buprenorphine) 5mcg/hr, 10mcg/hr, 20mcg/hr transdermal patch by Purdue The FDA has approved Purdue's Butrans (buprenorphine) Transdermal System for the management of moderate to severe ...
Medindia

The Efficacy and Safety of Butrans (buprenorphine) Transdermal System in Opioid-Naive Patients with Moderate to Severe Low Back Pain: A Double-Blind Study

NATIONAL HARBOR, Md., March 25, 2011 /PRNewswire-USNewswire/ -- Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans ...
Business Wire

Purdue Pharma L.P. To Present Data from Clinical Program for Butrans™ (buprenorphine) Transdermal System CIII At PAINWeek® 2010

Three strengths of Butrans will be available: 5, 10, and 20 mcg/hour; each single transdermal system is intended to be worn for seven days. Do not exceed a dose of one 20 mcg/hour Butrans system due ...
Medindia

Purdue Pharma L.P. Receives FDA Approval for Butrans(TM) (buprenorphine) Transdermal System CIII

STAMFORD, Conn., July 1 Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Butrans(TM) (buprenorphine) Transdermal System CIII for the management of moderate ...
Pharmabiz

Purdue Pharma gets US FDA nod for 15 mcg/hour dosage strength of Butrans transdermal system CIII

Purdue Pharma has received the US Food and Drug Administration (FDA) approval for a new 15 mcg/hour dosage strength of Butrans (buprenorphine) Transdermal System CIII, which will provide an additional ...
Medscape

FDA Clears New Dosage for Buprenorphine Pain Patch

The US Food and Drug Administration (FDA) has approved a new 15-μg/hour dosage strength of Purdue Pharma's once-weekly buprenorphine transdermal system (Butrans) for the management of moderate to ...
Yahoo Finance

Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales of $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm

ORLANDO, FL / ACCESSWIRE / October 11, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has completed ...
FiercePharma

Purdue Pharma L.P. Receives FDA Approval For 15 mcg/hour Dosage Strength Of Butrans® (Buprenorphine) Transdermal System CIII

STAMFORD, Conn., Sept. 24, 2013 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food and Drug Administration (FDA) approved a new 15 mcg/hour dosage strength of Butrans® (buprenorphine) ...
FiercePharma

Purdue Pharma L.P. Receives FDA Approval for 7.5 mcg/hour Dosage Strength of Butrans® (Buprenorphine) Transdermal System CIII

Purdue Pharma L.P. Receives FDA Approval for 7.5 mcg/hour Dosage Strength of Butrans® (Buprenorphine) Transdermal System CIII FDA also approves the use of two Butrans patches for dose adjustments in ...
The Globe and Mail

Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales 0f $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm

ORLANDO, FL / ACCESSWIRE / October 11, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has completed ...